[Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
In 38 patients with Parkinson's syndrome Madopar preparation was used (L-dopa with peripheral decarboxylase inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L-dopa. In the group of 33 patients 39 could complete the treatment, one patient died suddenly, three had the treatment withdrawn in view of side effects. The effectiveness of Madopar was assessed by means of five-rate scoring systems NUDS and ART. Clinical improvement was found in 22 cases (about 67%). The improvement included mainly bradykinesia and rigidity, while tremor was only slightly improved. Side effects developed in about 40% of patients and were slight and transient (apart from 3 cases). The main contraindications seem to be psychotic disturbances. In the group of 5 cases treated with Madopar as an additional drug in low doses improved the result of long-term treatment with L-dopa.
D000328:Adult; D000368:Aged; D001545:Benserazide / Q000627:therapeutic use*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors / Q000378:metabolism; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010525:Peripheral Nerves / Q000201:enzymology
D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide; D002262:Carboxy-Lyases
Leczenine parkinsonizmu L-dopa i inhibitorem dekarboksylazy obwodowej